Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Mesirow Institutional Investment Management Inc.

Mesirow Institutional Investment Management Inc. lessened its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 8.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 380,389 shares of the company's stock after selling 33,560 shares during the period. Mesirow Institutional Investment Management Inc. owned about 0.79% of Amphastar Pharmaceuticals worth $14,124,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AMPH. Smartleaf Asset Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares during the period. Parkside Financial Bank & Trust increased its stake in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares during the last quarter. Huntington National Bank lifted its position in Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after buying an additional 361 shares during the period. TD Private Client Wealth LLC boosted its stake in Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after buying an additional 388 shares during the last quarter. Finally, KBC Group NV grew its holdings in Amphastar Pharmaceuticals by 43.1% in the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after buying an additional 650 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ AMPH traded down $0.37 during midday trading on Wednesday, hitting $23.56. The stock had a trading volume of 317,436 shares, compared to its average volume of 464,233. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 7.85, a PEG ratio of 2.19 and a beta of 0.79. The company has a fifty day moving average price of $27.46 and a 200 day moving average price of $36.97.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the transaction, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.